Core 2: Neuro-Imaging Core (NIC)

核心 2：神经影像核心 (NIC)

• 批准号: 10673771
• 负责人: Benjamin M. Ellingson
• 金额: $ 19.17万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-11 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673771
• 关键词: Address; Amines; Anatomy; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Archives; BCL2L1 gene; Beds; Biological Markers; Blood Vessels; Blood Volume; Brain; CD8B1 gene; Caliber; Cataloging; Cell Density; Cellularity; Clinic; Clinical; Clinical Trials; Companions; Complex; Computer software; Corpus striatum structure; Data; Diffusion; Diffusion Magnetic Resonance Imaging; Dopamine; EGFR inhibition; Environment; Evaluation; Functional Imaging; Glioblastoma; Glioma; Goals; Growth; Guidelines; Human; Image; Imaging Techniques; Imaging technology; ImmunoPET; Immunotherapy; In Situ; Individual; International; Link; Macrophage; Magnetic Resonance Imaging; Malignant neoplasm of brain; Measurement; Metabolic; Patient imaging; Patients; Perfusion; Phenotype; Physiological; Positron-Emission Tomography; Procedures; Process; Prognosis; Protocols documentation; Public Health; Radiation; Recurrent tumor; Reproduction spores; Research; Research Personnel; Resolution; Resources; Secure; Standardization; T-Lymphocyte; Techniques; Therapeutic; Therapeutic Clinical Trial; Tracer; Translations; Tumor Biology; Tumor-associated macrophages; Vascular Permeabilities; anatomic imaging; brain tissue; brain tumor imaging; clinical imaging; effective therapy; experience; ferumoxytol; fluorodeoxyglucose; fluorodeoxyglucose positron emission tomography; imaging approach; in vivo; indexing; insight; metabolic imaging; molecular imaging; neoplastic cell; neuro-oncology; neuroimaging; novel; novel therapeutic intervention; novel therapeutics; perfusion imaging; pre-clinical; preclinical imaging; presynaptic; radiological imaging; response; subventricular zone; tool; treatment response; tumor; tumor metabolism; tumor microenvironment

PROJECT SUMMARY/ABSTRACT – Neuro-Imaging Core (NIC) The extremely poor prognosis and lack of effective treatments for glioblastoma (GBM) remains a significant public health issue. While traditional MRI techniques are valuable in determining GBM response to common anti-neoplastic therapies, novel treatments including immunotherapies, anti-angiogenic agents, or therapies that alter tumor metabolism may result in radiographic changes that are challenging to differentiate from non- responsive or growing tumor. Therefore, the primary goal of the Neuro-Imaging Core (NIC) will be to provide advanced MRI and PET imaging support with established reliability and consistency to SPORE project investigators for their respective projects. Specifically, the NIC will use quantitative µMRI and µPET for pre- clinical imaging (Aim 1) and state-of-the-art MR and PET imaging acquisition, advanced post-processing, and novel analysis tools for clinical imaging of patients in novel clinical trials (Aim 2). Additionally, we will provide professional expertise and resources for traditional and enhanced radiographic response assessment for the clinical trials for individual SPORE projects (Aim 3). Hence, this Core will add value to the overall SPORE by helping investigators to better understand the in situ metabolic, physiologic, functional, and traditional radiographic changes within the brain and tumor to address specific objectives of each of the UCLA Brain Cancer SPORE projects. Another main goal of the NIC is to understand the link between metabolic and/or physiologic imaging and tumor biology to reliably delineate treatment response versus recurrent tumor, which in turn will facilitate the direct translation of new MR-PET companion biomarkers/techniques to the clinic for the evaluation of treatment response in ongoing and new therapeutic clinical trials resulting from the SPORE projects and cores.

项目总结/摘要-神经成像核心（NIC） 胶质母细胞瘤（GBM）的极差预后和缺乏有效治疗仍然是一个重要的问题。 公共卫生问题。虽然传统的MRI技术在确定GBM对常见肿瘤的反应方面很有价值， 抗肿瘤治疗、包括免疫治疗的新治疗、抗血管生成剂或治疗 改变肿瘤代谢可能导致放射学改变， 反应性或生长性肿瘤。因此，神经成像核心（NIC）的主要目标是提供 先进的MRI和PET成像支持，与SPORE项目具有既定的可靠性和一致性 他们各自的研究项目。具体而言，NIC将使用定量µMRI和µPET进行预处理， 临床成像（目标1）和最先进的MR和PET成像采集，先进的后处理，以及 用于新型临床试验中患者临床成像的新型分析工具（目标2）。此外，我们将提供 传统和增强型放射学反应评估的专业知识和资源， 针对单个SPORE项目的临床试验（目标3）。因此，该核心将通过以下方式为整个SPORE增加价值： 帮助研究人员更好地了解原位代谢，生理，功能和传统 脑和肿瘤内的放射学变化，以解决每个UCLA脑的特定目标 癌症孢子项目。NIC的另一个主要目标是了解代谢和/或代谢异常之间的联系。 生理成像和肿瘤生物学，以可靠地描述治疗反应与复发肿瘤， 反过来，这将有助于将新的MR-PET伴随生物标志物/技术直接转化为临床， 在SPORE导致的正在进行的和新的治疗性临床试验中评价治疗反应 项目和核心。